Annual CFI
-$31.35 M
-$191.66 M-119.55%
December 31, 2023
Summary
- As of February 7, 2025, NTLA annual cash flow from investing activities is -$31.35 million, with the most recent change of -$191.66 million (-119.55%) on December 31, 2023.
- During the last 3 years, NTLA annual CFI has risen by +$183.14 million (+85.39%).
- NTLA annual CFI is now -119.55% below its all-time high of $160.31 million, reached on December 31, 2022.
Performance
NTLA Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFI
-$7.71 M
+$16.48 M+68.13%
September 30, 2024
Summary
- As of February 7, 2025, NTLA quarterly cash flow from investing activities is -$7.71 million, with the most recent change of +$16.48 million (+68.13%) on September 30, 2024.
- Over the past year, NTLA quarterly CFI has dropped by -$87.21 million (-109.70%).
- NTLA quarterly CFI is now -108.09% below its all-time high of $95.34 million, reached on June 30, 2022.
Performance
NTLA Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFI
$19.94 M
-$87.21 M-81.39%
September 30, 2024
Summary
- As of February 7, 2025, NTLA TTM cash flow from investing activities is $19.94 million, with the most recent change of -$87.21 million (-81.39%) on September 30, 2024.
- Over the past year, NTLA TTM CFI has increased by +$127.38 million (+118.56%).
- NTLA TTM CFI is now -87.56% below its all-time high of $160.31 million, reached on December 31, 2022.
Performance
NTLA TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Investing Formula
CFI = Cash Inflows from Investments − Cash Outflows for Investments
NTLA Cash From Investing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -119.5% | -109.7% | +118.6% |
| 3 y3 years | +85.4% | +98.1% | +103.3% |
| 5 y5 years | +88.0% | +75.6% | -20.8% |
NTLA Cash From Investing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -119.5% | +94.3% | -108.1% | +95.2% | -87.6% | +103.6% |
| 5 y | 5-year | -119.5% | +94.3% | -108.1% | +98.1% | -87.6% | +103.3% |
| alltime | all time | -119.5% | +94.3% | -108.1% | +98.1% | -87.6% | +103.3% |
Intellia Therapeutics Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$7.71 M(-68.1%) | $19.94 M(-81.4%) |
| Jun 2024 | - | -$24.19 M(-509.9%) | $107.15 M(+10.7%) |
| Mar 2024 | - | $5.90 M(-87.2%) | $96.80 M(-408.8%) |
| Dec 2023 | -$31.35 M(-119.6%) | $45.94 M(-42.2%) | -$31.35 M(-70.8%) |
| Sep 2023 | - | $79.50 M(-330.2%) | -$107.44 M(-22.9%) |
| Jun 2023 | - | -$34.54 M(-71.7%) | -$139.29 M(+1380.0%) |
| Mar 2023 | - | -$122.25 M(+305.4%) | -$9.41 M(-105.9%) |
| Dec 2022 | $160.31 M(-129.1%) | -$30.15 M(-163.3%) | $160.31 M(+411.4%) |
| Sep 2022 | - | $47.64 M(-50.0%) | $31.35 M(-107.5%) |
| Jun 2022 | - | $95.34 M(+100.8%) | -$415.68 M(-13.0%) |
| Mar 2022 | - | $47.47 M(-129.8%) | -$477.76 M(-13.3%) |
| Dec 2021 | -$550.78 M(+156.8%) | -$159.12 M(-60.2%) | -$550.78 M(-8.6%) |
| Sep 2021 | - | -$399.38 M(-1300.8%) | -$602.58 M(+68.7%) |
| Jun 2021 | - | $33.26 M(-230.2%) | -$357.18 M(+20.1%) |
| Mar 2021 | - | -$25.54 M(-87.9%) | -$297.48 M(+38.7%) |
| Dec 2020 | -$214.49 M(-952.0%) | -$210.92 M(+37.0%) | -$214.49 M(-982.1%) |
| Sep 2020 | - | -$153.98 M(-265.6%) | $24.32 M(-83.4%) |
| Jun 2020 | - | $92.96 M(+61.8%) | $146.64 M(+90.6%) |
| Mar 2020 | - | $57.45 M(+106.0%) | $76.93 M(+205.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2019 | $25.18 M(-109.7%) | $27.88 M(-188.1%) | $25.18 M(-109.7%) |
| Sep 2019 | - | -$31.65 M(-236.1%) | -$258.72 M(+12.9%) |
| Jun 2019 | - | $23.25 M(+308.2%) | -$229.09 M(-9.5%) |
| Mar 2019 | - | $5.70 M(-102.2%) | -$253.24 M(-2.9%) |
| Dec 2018 | -$260.78 M(+2484.3%) | -$256.02 M(>+9900.0%) | -$260.78 M(+3540.7%) |
| Sep 2018 | - | -$2.02 M(+124.0%) | -$7.16 M(-3.3%) |
| Jun 2018 | - | -$900.00 K(-51.4%) | -$7.41 M(-4.8%) |
| Mar 2018 | - | -$1.85 M(-22.8%) | -$7.78 M(-22.9%) |
| Dec 2017 | -$10.09 M(+63.7%) | -$2.40 M(+6.1%) | -$10.09 M(-9.1%) |
| Sep 2017 | - | -$2.26 M(+77.7%) | -$11.10 M(+17.5%) |
| Jun 2017 | - | -$1.27 M(-69.4%) | -$9.44 M(+1.3%) |
| Mar 2017 | - | -$4.16 M(+22.2%) | -$9.32 M(+51.2%) |
| Dec 2016 | -$6.17 M(+141.4%) | -$3.40 M(+462.8%) | -$6.17 M(+70.8%) |
| Sep 2016 | - | -$605.00 K(-47.3%) | -$3.61 M(+0.1%) |
| Jun 2016 | - | -$1.15 M(+13.8%) | -$3.61 M(+18.4%) |
| Mar 2016 | - | -$1.01 M(+18.7%) | -$3.05 M(+19.3%) |
| Dec 2015 | -$2.55 M | -$849.00 K(+41.0%) | -$2.55 M(+49.8%) |
| Sep 2015 | - | -$602.00 K(+2.6%) | -$1.71 M(+54.6%) |
| Jun 2015 | - | -$587.00 K(+13.8%) | -$1.10 M(+113.8%) |
| Mar 2015 | - | -$516.00 K | -$516.00 K |
FAQ
- What is Intellia Therapeutics annual cash flow from investing activities?
- What is the all time high annual CFI for Intellia Therapeutics?
- What is Intellia Therapeutics annual CFI year-on-year change?
- What is Intellia Therapeutics quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Intellia Therapeutics?
- What is Intellia Therapeutics quarterly CFI year-on-year change?
- What is Intellia Therapeutics TTM cash flow from investing activities?
- What is the all time high TTM CFI for Intellia Therapeutics?
- What is Intellia Therapeutics TTM CFI year-on-year change?
What is Intellia Therapeutics annual cash flow from investing activities?
The current annual CFI of NTLA is -$31.35 M
What is the all time high annual CFI for Intellia Therapeutics?
Intellia Therapeutics all-time high annual cash flow from investing activities is $160.31 M
What is Intellia Therapeutics annual CFI year-on-year change?
Over the past year, NTLA annual cash flow from investing activities has changed by -$191.66 M (-119.55%)
What is Intellia Therapeutics quarterly cash flow from investing activities?
The current quarterly CFI of NTLA is -$7.71 M
What is the all time high quarterly CFI for Intellia Therapeutics?
Intellia Therapeutics all-time high quarterly cash flow from investing activities is $95.34 M
What is Intellia Therapeutics quarterly CFI year-on-year change?
Over the past year, NTLA quarterly cash flow from investing activities has changed by -$87.21 M (-109.70%)
What is Intellia Therapeutics TTM cash flow from investing activities?
The current TTM CFI of NTLA is $19.94 M
What is the all time high TTM CFI for Intellia Therapeutics?
Intellia Therapeutics all-time high TTM cash flow from investing activities is $160.31 M
What is Intellia Therapeutics TTM CFI year-on-year change?
Over the past year, NTLA TTM cash flow from investing activities has changed by +$127.38 M (+118.56%)